Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
In this article:
Liquidia stock retook its 50-day line on a U.S. judge's ruling on a patent dispute with United Therapeutics.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Liquidia stock retook its 50-day line on a U.S. judge's ruling on a patent dispute with United Therapeutics.